Ovarian Cancer Research Foundation Annual Report 2023-24

2023-24 ANNUAL REPORT

STEPPING UP

Vision

Purpose

A healthy vibrant future for all those impacted by ovarian cancer.

We exist to drive step-change in funds raised, awareness, and research undertaken, for the most lethal women’s cancer in Australia.

About the OCRF Ovarian Cancer Research Foundation (OCRF) is Australia’s largest independent funder of ovarian cancer medical research and a leading advocate for improving outcomes for this devastating disease.

Ovarian cancer is one of the most lethal cancers with a five-year survival rate that has barely changed in 30 years, languishing at under 50 per cent. It is also chronically underfunded. Addressing health disparity and funding inequity in cancer research is fundamental to achieving higher survival rates for ovarian cancer.

The OCRF is driving a step-change to rewrite this bleak narrative. Our vision is a healthy, vibrant future for all those affected by ovarian cancer, a goal that we are achieving through greater awareness, effective collaboration and advocacy, and funding the most talented researchers and promising projects. This is made possible by funds raised by the Australian community, people who share our vision and are determined to do something to make it a reality.

OCRF galvanises community efforts to generate critical funds to enable these efforts, investing over $30 million since 2000. OCRF funds are 100 per cent raised by the Australian community: dedicated corporate partners as well as mothers, fathers, sisters, brothers, sons and daughters, other family and friends, stepping up to raise urgently needed money for this important cause.

Guided by an International Scientific Advisory Committee and Consumer Representative Panel, OCRF funding targets four key areas: prevention, early detection, better treatments and managing recurrence. Investments focus on support for earlyand mid-career ovarian cancer scientists, via the annual OCRF National Research Grants Scheme.

OCRF is a strong voice for collective action — advocating in collaboration with others in the sector, our partners, and the community, to improve outcomes for ovarian cancer patients now, and for future generations.

Front cover: Amelia, Laura and Anabel Flynn, captured in the 2024 Witchery White Shirt Campaign. The three sisters continue to advocate alongside the OCRF in honour of their late mother Leane Flynn, who passed away in September 2023. A fierce and dedicated ambassador from the moment she was diagnosed with ovarian cancer until her last days, Leane touched thousands of people across the country and the world by so candidly and openly sharing her personal journey. Her legacy is upheld by her three daughters as they step up to continue their mum’s work in the hope to change ovarian cancer outcomes for future generations.

This page: High grade serous ovarian cancer cells.

2

|

Ovarian Cancer Research Foundation

Contents 2023-24 at a glance

4

1. Executive reports

5

2. Research impact

7

3. Advocacy

15

4. Major partnerships

19

5. Donors, appeals and fundraising

25

6. Community

29

7. Financial statements, acknowledgements, governance

33

The challenge we face

42

The Ovarian Cancer Research Foundation acknowledges the traditional custodians of the lands upon which we work, strive and learn, the Wurrundjiri Woi wurrung and Bunorung Boon wurrung peoples of the Kulin nation.

We pay our respects to Elders past and present and extend this respect to all Aboriginal and Torres Strait Islander peoples in Australia and beyond.

Annual report 2023–24

|

3

2023-24 at a glance Total revenue

Community ambassadors

$5.99m

90

Other income $0.25m Partnerships $2.14m Donors, appeals and fundraising $3.6m

Total revenue $5.99m

E-news subscribers

Awareness

New research grants awarded

1,930 Media mentions 1.14b Reach 37,513 Social media followers

|

$1.69m

Unique donations

25k

4

In kind contributions

Ovarian Cancer Research Foundation

pro bono

57k

$2.4m

OCRF National Research Grants Scheme and Collaborative Grants

Chairperson report Stepping up As the OCRF approaches its 25th anniversary in 2025, it’s evident that the foundation is really coming of age. In the pages of this report, there’s a genuine sense of momentum and a shifting of gears. We have a new emphasis on activism and advocacy, developing a stronger platform, influence and voice, that is demanding of change and determined to drive it.

It’s an exciting time for the OCRF – a time of hope and growth. We are propelled by ovarian cancer survival statistics that remain woefully static, and projections for incidence and deaths that are simply unacceptable. More importantly we are driven by the stories of the women and girls in our community and the impact this terrible disease continues to have on their lives and society.

The board, the staff and the OCRF community are resolute that we must, and will, see change that will reverse the trend and rewrite this narrative.

In the past year, under our energetic CEO Robin Penty, the OCRF team has been restructured, furthering our capability and capacity in enabling and supporting high-potential research, across all aspects of the business.

At a board level, I would like to recognise and thank our current Board and subcommittee members, and offer special acknowledgement of outgoing board members Ms Sarah Saunders and The Hon Lisa Neville for their contribution to our vision. We warmly welcome new Board Director, Ms Karleen Radford and Board Observer Ms Melanie Hayden, who were appointed in June 2024.

The foundation is in an excellent position to grow as we head into our Silver Anniversary year.

As part of this, I’d like to highlight the expansion of our community and corporate partnerships, which do so much to help put ovarian cancer in the public eye and raise the much-needed funds to make the research possible.

And, of course, we couldn’t do any of it – and wouldn’t be the passionate, driven organisation that we are - without the broader community of OCRF donors, supporters, volunteers, ambassadors and advocates who fuel everything we do.

Together we raised $5.996 million in 2023-24 and received $1.688 million in pro bono support. On behalf of the OCRF Board, thank you to everyone who gave so generously toward a healthy future for all those impacted by ovarian cancer.

As we continue our efforts into 2025 and beyond, we also pay tribute to the lives of those lost to this insidious disease over the past year.

I am proud of our progress and excited about future possibilities and potential for the OCRF on a global stage as well. We will increase our funding and impact in research, we will agitate for more government investment, and we will continue to build awareness and community as a core part of our purpose.

And together, we will overcome ovarian cancer.

Julie Toop

Annual report 2023–24

|

5

CEO report Stronger, together.

Over the past year, OCRF has cemented its reputation as an organisation of integrity, insight, national and international reach.

Our impact is both wide and deep: we are a rigorous grant-making and fundraising body; a vocal advocate for equity in women’s health, and for change; a community builder; and a trusted partner, walking hand in hand with our passionate community of supporters.

2024 saw us build our research, donor, partnerships and communications teams with highly skilled, passionate and dedicated staff, reinforcing our team ahead of an exciting new chapter of investment and growth, as we strive to take OCRF’s impact to the next level.

In this report, there’s evidence of the progress our talented team has already made, with increased funding for medical research, major new partnerships, expansion of existing ones, delivery of a strong grants round of high-potential research and a highly publicised commercialisation announcement. We’ve been so pleased to welcome an ever-expanding contingent of supporters as well, from donors to researchers, high-profile spokespeople, and a growing group of community ambassadors.

I’m proud that the OCRF continues to be a trusted national voice in ovarian cancer research, with strong, respectful relationships across the sector.

We have also established ourselves as a bright, shining example of how to fundraise for ovarian cancer with courage, flair and heart.

featured a diverse list of 45 well-known Australian women to support this cause.

We’ve placed increased emphasis on connection and collaboration with other proponents in ovarian cancer, working to strengthen our voice, presence and profile with Government as an allied force with a shared vision. This will powerfully shift perceptions and enhance our capacity to influence outcomes, and we have already made important in-roads in this space.

Most importantly, I feel a huge sense of gratitude and responsibility to everyone who donates time, money or resources to the OCRF. Every dollar that we grant to researchers and use to raise awareness and advocate comes from the Australian community. What we do, what we achieve – is, quite literally, only possible due to such support.

Robin Penty

As just one example, the OCRF won an international award from our peers at the World Ovarian Cancer Coalition this year in the category of Inspiring Collaborations, an acknowledgement of our ongoing creative partnership with Witchery for the glorious White Shirt campaign, which this year Facing page: 2024 National Research Grants Scheme recipient, Prof Kristen Radford

6

|

Ovarian Cancer Research Foundation

RESEARCH IMPACT ‘This year was pivotal for enhancing the OCRF’s ability to drive impactful ovarian cancer research. We underwent a thorough review and consultation process, emphasising that we are stronger and more effective when we work together.’

Annual report 2023–24

|

7

Research impact A year of review, collaboration and consultation This year, the OCRF announced one of its largest ever funding commitments: $2.4 million allocated through our National Research Grants Scheme and Collaborative Grants Scheme. This funding supports critical research projects focused on innovative treatments, managing recurrence, and early detection of ovarian cancer.

In August, a long-term OCRF-funded early detection research project in Melbourne took a significant step forward, moving from laboratory to a commercialisation. The search for more effective ovarian cancer treatments is yielding exciting advances too, with OCRF-funded research identifying new treatment opportunities.

This year was also pivotal for enhancing the OCRF’s ability to drive impactful ovarian cancer research. We underwent a thorough review and consultation process, emphasising that we are stronger and more effective when we work together. As a result, OCRF formalised several important partnerships, both domestically and internationally.

Our newly established research team actively sought input from key stakeholders involved in tackling the complexities of ovarian cancer.

‘In a multidisciplinary and multi-institute effort across Australia and overseas, we have access to a large number of samples from patients with different types of cancers and other pro-inflammatory conditions. This will enable us to establish the disease specificity of OCRF-7 and determine its accuracy in distinguishing ovarian cancer from other types of cancers.”

– Prof Carlos Salomon Gallo Professor Carlos Salomon Gallo and his research team at The University of Queensland

8

|

Ovarian Cancer Research Foundation

RESEARCH HIGHLIGHTS Exploring the frontiers of immunotherapy for ovarian cancer: Dr Sherry Wu, University of Queensland Immunotherapies have generally not been as effective against ovarian cancer as with other cancer types. In March, researchers published exciting findings raising hopes that this could change. Building on a project funded by OCRF in 2018, Dr Wu’s promising new therapy harnesses a molecule called Let-7i and was able to reduce tumour-size by approximately 95 per cent.

An innovative cell-targeting treatment system for ovarian cancer: Professor Carlos Salomon Gallo, University of Queensland In June, researchers published exciting results of a new treatment system that uses engineered extracellular vesicles to target ovarian cancer cells. The project, co-funded by the OCRF, has the potential to increase the effectiveness of ovarian cancer treatments already approved for clinical use to improve patient outcomes. If this approach proves effective in pre-clinical models, the researchers hope to progress to a clinical trial in 2025.

Accelerating research progress: research sector consultations In April, OCRF teamed up with Insight Economics, the group behind the influential report ‘State of the Nation in Ovarian Cancer’ published in 2020, for a series of workshops exploring the opportunities to accelerate research progress.

The team conducted six highly valuable and insightful workshops with more than 50 leading ovarian cancer researchers to discuss the structural needs of the academic research sector.

consultations will add insights from the patient perspective, via a survey and workshops aimed at addressing two essential questions: How can the OCRF better engage consumers in research? and What types of research should the OCRF prioritise?

These consultations will inform a new research plan and strategy, set to be published in early 2025.

This plan, guided by our community’s input, will outline our vision for accelerating progress toward a healthy, vibrant future for everyone affected by ovarian cancer.

An international roadmap: the Helene Harris Memorial Trust International Forum in Ovarian Cancer In October 2024, OCRF will join Ovarian Cancer Action (UK), Ovarian Cancer Research Alliance (USA) and Ovarian Cancer Canada, as the first-ever Global Partners and sponsors of the Helene Harris Memorial Trust (HHMT) International Forum in Ovarian Cancer. OCRF has nominated two leading Australian researchers to join their international peers in identifying and publishing a roadmap for research progress against high grade serous ovarian cancer (HGSOC), the most common and most lethal variant.

Together with our peer charity CEOs from Ovarian Cancer Action UK, Ovarian Cancer Canada, and Ovarian Cancer Research Alliance (US), the OCRF intends to contribute to an expanded vision and potential collaborative project to accelerate research outcomes world-wide.

The Insight Economics team focused on three key areas: Capacity and Capability, Infrastructure, and Knowledge Sharing. Later this year, consumer

Annual report 2023–24

|

9

Enabling high potential projects In February the OCRF announced the recipients of our annual National Research Grants Scheme.

Three significant medical research grants totalling $2.1 million were awarded to Australian researchers tackling three distinct aspects of ovarian cancer.

The projects selected by the OCRF’s International Scientific Advisory Committee and Consumer Representative Panel included a novel early detection blood test, a vaccine to treat recurrence, and a drug combination treatment to target a rare subtype of the disease, low-grade serous ovarian cancer.

An additional $300,000 was distributed through co-funding of collaborative research projects.

Ovarian cancer is not one disease. It has multiple subtypes, each posing their own unique challenges.

Today’s patients urgently need targeted treatments while early detection and preventative solutions could save countless lives in the future. A multifaceted approach provides the required balance, and this is reflected in the 2024 grants.

$2.4m

awarded in new research grants

$4.17m

OCRF National Research Grants Scheme 2024 OCRF research priority: Early detection SIERRA study: Specificity of a new test for ovarian cancer Lead researcher: Professor Carlos Salomon Gallo Grant received: $940,000 over three years Research institution: Centre for Clinical Research, The University of Queensland Associated institutions: Mater Research Institute, Western Sydney University, Melbourne Royal Women’s Hospital, Mercy Hospital, The University of Western Australia Medical School, University College London, National University of Singapore, The Australian National University.

This project builds upon promising work in early detection. Researchers have already developed a test, named “OCRF-7” in recognition of OCRF’s longterm investment, trained to read tiny bubble-like secretions released from cells into the blood stream (extracellular vesicles). The SIERRA study will now determine whether the OCRF-7 test can detect high grade serous ovarian cancer with the highest level of accuracy, and if so, position it to progress as a diagnostic test for ovarian cancer.

CRF research priority: New and effective O treatments, managing recurrence A novel vaccine for ovarian cancer

ongoing grant commitments

Lead researcher: Professor Kristen Radford Grant received: $672,000 over three years Research institution: Mater Research Funded institution: The University of Queensland Associated institution: Icahn School of Medicine, Mt Sinai

22

The aim of this project is to develop a vaccine that treats ovarian cancer by improving the immune system’s ability to recognise and eliminate cancer cells. The research team will investigate which molecules on dendritic cells could be targeted to train the immune system to fight cancer more effectively.

to June 2027

supported projects

10

|

Ovarian Cancer Research Foundation

OCRF research priority: New and effective

treatments, managing recurrence Validation of new treatments for low-grade serous ovarian cancer

Lead researcher: Dr Dane Cheasley Grant received: $482,000 over three years Research Institution: Cancer Evolution and Metastasis Program, The Peter MacCallum Cancer Centre Funded Institution: The University of Melbourne Associated Institutions: The University of British Columbia, Vancouver General Hospital, The University of Newcastle, Walter and Eliza Hall Institute for Medical Research, Victoria This project will look for a more effective way to combat one of the rarer types of ovarian cancer: low grade serous. Researchers have already identified twenty promising drugs, all already approved by the Therapeutic Goods Administration.

This study will aim to identify the most promising drug combinations with the least side effects, in order to inform a new targeted treatment.

OCRF research priority: Managing recurrence Lead researcher: Dr Alexander Cole OCRF grant received: $100,000 over two years Co-funder: Cancer Australia, Priority-driven Collaborative Cancer Research Scheme (matched funding) Research Institution: Centenary Institute, NSW In advanced stages of ovarian cancer, about 70 per cent of patients develop resistance to chemotherapy, which can reduce 5-year survival rates to below 30 per cent. At the Centenary Institute, researchers found that ovarian cancer cells often produce a protein called follistatin, which contributes to drug resistance. This limits treatment options for patients.

The goal of this project is to neutralize follistatin using an innovative drug that acts like a sponge, soaking up the excess follistatin produced by ovarian cancer cells.

Collaborative Grants Scheme 2024 OCRF research priority: New and effective treatments Lead researcher: Dr Jacinta Simmons OCRF grant received: $300,000 over three years Co-funder: Australian Cancer Research Foundation Research Institution: QIMR Berghofer Support for a post-doctoral researcher for three years. The project will see cutting edge technologies applied to one of the most fundamental challenges in ovarian cancer research: effective treatment.

Focusing on the most common subtype of ovarian cancer, high grade serous ovarian cancer (HGSOC), the OCRF’s contribution will enable the examination of why some patients respond well to PARP inhibitors, while others develop resistance. This will help identify the best treatment options for therapy-resistant patients and progress the most promising findings to validation.

2024 OCRF National Research Grants Scheme recipients Dr Dane Cheasley, Professor Carlos Salomon Gallo, Professor Kristen Radford

“This grant enables us to take a key finding from the lab and work to translate it into a novel therapy we hope will improve outcomes. We previously demonstrated inhibiting this mechanism in mouse models of ovarian cancer improved overall survival. If we can replicate this effect in humans, we could have a significant impact on this devastating disease.”

– Dr Alexander Cole

Annual report 2023–24

|

11

Major step for OCRF-supported surgical triage test

The successful implementation of the Cleo Triage Test could yield significant benefits for the broader healthcare system and community:

Research funded by the OCRF for over a decade reached a significant milestone: moving from the laboratory to the commercialisation phase by listing on the Australian Stock Exchange in August 2023. This exciting development is focusing on the introduction of an improved diagnostic test for ovarian cancer.

• Potential reductions in healthcare costs for the government, hospitals, and health insurers • Better outcomes for women with benign tumours and more efficient use of surgical resources • Better prioritisation in the allocation of surgical beds and facilities • Decreased hospital stays and associated community benefits.

The Cleo Triage Test, developed at the Hudson Institute of Medical Research in Melbourne by Dr Andrew Stephens and his team, is an innovative blood test designed to accurately differentiate between benign and malignant ovarian growths. This test is being commercialised by Cleo Diagnostics Ltd, aiming to enhance ovarian cancer diagnosis, reduce unnecessary surgeries, and ultimately improve patient outcomes while saving healthcare resources.

Major advantages

The OCRF is proud to have supported this research journey for over twelve years, providing essential early and seed funding. This long-term commitment has been crucial in translating research into a viable clinical application.

Cleo Diagnostics successfully completed its IPO in July 2023, allowing for funding to advance the test’s development and validation. The goal is to transition the test to clinical use by 2025, with plans for expanded testing in additional markets.

Currently, women facing abnormal ovarian growths endure significant anxiety and uncertainty due to insufficient diagnostic methods. The traditional approach often involves a combination of a CA-125 blood test and an ultrasound, which can lead to invasive surgeries for definitive diagnosis, causing unnecessary trauma. The Cleo Triage Test offers several key advantages: • a reliable cancer diagnostic assessment before surgical intervention • offering high sensitivity and specificity, the test enables effective referrals to gynaecological oncology specialists based on clear diagnostic results • allows for more appropriate management strategies for non-cancerous growths, minimizing unnecessary interventions • eases the emotional burden on patients by providing timely and accurate information regarding their condition.

Professor Tom Jobling, who is the Lead Medical Advisor for Cleo Diagnostics, emphasised that this test is intended to enhance the efficiency of the surgical referral process and ensure optimal management for all patients.

12

|

Ovarian Cancer Research Foundation

OCRF team celebrate the listing of Cleo Diagnostics on the ASX

Scan the QR code to learn more

Ongoing projects The OCRF provides multi-year funding to high potential ovarian cancer research projects in medical research institutions around Australia. In addition to this year’s five new grants, there are 14 active research projects currently receiving funding support from the OCRF, and a further three receiving in-kind support.

Table 1: OCRF-funded research projects Research pillar(s)

Project

Chief Investigator

Institute*

Planned completion

Funding paid in 2023/24

New and effective treatments

Precision Medicine for Ovarian Cancer

Dr Maree Bilandzic

HIMR

Sept 2023

$40,470

New and effective treatments

Leveraging genomics to overcome drug resistance

Prof Stacey Edwards

QIMR Berghofer

Dec 2024

$156,862

Early detection

Blood-based protein biomarker for EDT

Prof Pradeep Tanwar

UoN

Dec 2024 (extension)

$198,365

New and effective treatments

Targeting tumour microenvironment

Prof Matthias Ernst

ONJCRI

June 2024

$148,553

New and effective treatments

Functional genomic approaches for identifying therapeutic targets

Prof Ron Firestein

HIMR

Dec 2024 (extension)

$105,382

Research Infrastructure

Adelaide Tissue Bank

Prof Martin Oehler

UoA

June 2025

$80,076

Research Infrastructure

Hudson Tissue Bank

Dr Maree Bilandzic

HIMR

June 2025

$146,269

New and effective treatments

Improving Immune Response

Prof Brian Gabrielli

UQ / Mater Research

June 2026

$167,630

Early detection

Early Detection using liquid biopsy circRNA (Lee)

A/Prof Jason Lee

QIMR Berghofer

June 2026

$278,129

Glycomarkers for Early Detection Neu5Gs

Prof Michael Jennings

Griffith University

June 2026

$444,203

Managing recurrence

Managing recurrence Early detection

*Please see list of institutes overleaf.

Annual report 2023–24

|

13

Table 2: Collaborative projects Research pillar

Co-funding Project partner

Research Chief Investigator

Institute Planned completion

OCRF contribution in 2023/24

Early detection

MRFF

Ovarian cancer early detection, monitoring and therapeutic intervention using extracellular vesicles

A/Prof Carlos Salomon

UQ

Aug 2024

$15,000

New and effective treatments

MRFF

A new radio-imaging agent to guide targeted therapy for epithelial ovarian cancer

Prof John Hooper

UQ

Aug 2024

$15,000

Early detection

MRFF

Towards a new era in Granulosa Cell Tumour

A/Prof Simon Chu

Hudson Institute

Nov 2024

$29,500

Prevention

MRFF

Machine learning genetic epidemiological study

Prof Elina Hypponen

UniSA

Dec 2025

In kind

Early detection

NHMRC

Enabling early ovarian cancer diagnosis and prediction of platinum resistance

Dist. Prof Magdalena Plebanski

RMIT

Dec 2025

In kind

Early detection

MRFF

A/Prof Implementing a Carlos multivariate index assay for the earlier detection of Salomon ovarian cancer

UQ

Dec 2025

In kind

New and effective treatments

ACRF

ACRF Centre for Precision Medicine

ONJCRI

June 2026

$100,000

New and effective treatments

Prof Andrew Scott

Co-funding partners: Australian Cancer Research Foundation (ACRF) Medical Research Future Fund (MRFF) National Health and Medical Research Council (NHMRC)

Institutes: Griffith University Hudson Institute of Medical Research (HIMR) Mater Research Olivia Newton-John Cancer Research Institute – La Trobe University (ONJCRI) Queensland Institute of Medical Research (QIMR Berghofer) Royal Melbourne Institute of Technology (RMIT) University of Adelaide (UoA) University of Newcastle (UoN) University of Queensland (UQ) University of South Australia (UniSA)

Facing page: OCRF team and ambassadors on White Shirt Day 2024

14

|

Ovarian Cancer Research Foundation

ADVANCING THE CAUSE ‘It is critical we work with others to fund high-potential research and optimise opportunities for translation from the laboratory bench to clinical trials, and ultimately enable development of safe, effective, accessible interventions.’

Annual report 2023–24

|

15

Advocacy #StrongerTogether As Australia’s leading independent funder of medical research in ovarian cancer and influential advocates, we are key drivers of critical and fundamental science and research. It is therefore critical we work with others to fund high-potential research and optimise opportunities for translation from the laboratory bench to clinical trials, and ultimately enable development of safe, effective, accessible interventions. That’s why we’re actively listening, connecting and adding our voice to a range of issues that, collectively, will help solve the problem and ultimately, save lives.

This year, OCRF joined forces with multiple organisations also working to improve the lives of people affected by ovarian cancer.

This collaborative approach has seen the development of several key relationships and participation in some influential forums both in Australia and internationally.

Robin Penty with Robyn Riley from the Herald Sun at Rare Cancers Awareness Day at the National Press Club, Canberra

16

|

Ovarian Cancer Research Foundation

Ambassador Dr Shabnam Gujadhur speaking at a local community event, QLD

Putting rare and less common gynae cancers on the agenda Since the beginning of the COVID pandemic over 90 million people have been diagnosed with cancer and 40 million have died. And those ratios are far worse if you look at rare cancers – which collectively make up 27 per cent of the whole.

OCRF CEO, Robin Penty and the OCRF leadership team have been active participants in discussions and developments in Canberra during the year, to ensure medical research for ovarian cancer is in focus.

This included: • attending the Rare Cancers Australia Awareness Day lunch at the National Press Club which heralded the launch of Rare Cancers Australia’s Rare Cancers Moonshot plan, to be delivered as part of the Australian Cancer Plan • outreach to key government ministers and other influential parties inviting participation in the Witchery White Shirt campaign, with acceptance from The Hon Ged Kearney MP, Assistant Minister for Health; Senator the Hon Anne Ruston MP, Shadow Minister for Health, and Senator the Hon Anika Wells MP, Minister for Aged Care and Sport • advocacy meetings in Canberra together with Ovarian Cancer Australia.

These interactions are key to enhancing OCRF’s funding efforts with advocacy aimed at boosting and leveraging our investment to maximise impact. With collective will and investment we can make real change and make all cancers manageable diseases, including ovarian cancer.

A gender lens on medical research OCRF CEO Robin Penty joined clinical gynae oncologists at the Australian Society of Gynaecologic Oncologists (ASGO) Annual Scientific Meeting in Hobart in April to learn about the latest advances in treatment and care.

As an invited speaker, Robin spoke on ‘Levelling the field: Disparities in funding for medical research’, a timely reminder of the importance of a gender lens on medical research.

The Path to Hope To mark World Ovarian Cancer Day, OCRF hosted a special Talking Research webinar ‘The Path To Hope on World Ovarian Cancer Day’. The event attracted over 120 registrants keen to hear leading ovarian cancer researchers, Prof David Bowtell and Dr Rachel Delahunty of Peter MacCallum Cancer Centre and the University of Melbourne discuss key research directions and latest treatments for ovarian cancer. They were joined by courageous OCRF ambassador Olivia Curtis, who is living with stage three low grade serous ovarian cancer.

Expertly facilitated by radio host Loretta Hart, this was a rare opportunity to learn about what’s happening direct from the lab, receiving very positive feedback from the audience with one stating: “I feel hopeful after watching this.”

“There is compelling evidence of structural inequity and impact of disparities for women and girls across all domains and metrics in medical research, which strongly correlates to inequity in women’s health more broadly. The bottom line is that the women’s health gap continues to cost lives and money.”

– CEO Robin Penty at ASGO

Annual report 2023–24

|

17

Collective impact in Ovarian Cancer Awareness Month In February 2023, the three leading proponents for ovarian cancer in Australia – OCRF, Ovarian Cancer Australia (OCA) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) – came together and signed a Statement of Collaborative Intent. This signalled a new era of collaboration and mutual support, illustrated by a shared theme for Ovarian Cancer Awareness month – Stronger Together.

The statement affirmed a shared commitment to working and advocating together to ensure ovarian cancer is a national priority and to drive the significant change needed to have a powerful impact on future generations.

Further to this, OCRF CEO Robin Penty attended Ovarian Cancer Australia’s annual Teal Ribbon Parliamentary Breakfast in Canberra. A line up of esteemed speakers featured Assistant Minister for Health and Aged Care, The Hon Ged Kearney MP, Shadow Minister for Health and Aged Care, Senator the Hon Anne Ruston, and then CEO of OCA, Associate Professor Anna Boltong. Associate Professor Boltong highlighted the importance of collaboration in the sector and the need for ongoing support to make a difference to the many women.

Together the three organisations welcomed the Australian Senate inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers in February. Since then, the organisations have met regularly throughout the year, developing closer ties as we work together on key advocacy initiatives to boost investment into this chronically underfunded area of women’s health.

We know we are stronger when we amplify each other’s voices and champion the important roles we each play in improving outcomes for people with a lived experience of ovarian cancer

Following page: Winning partnership – Assoc Prof Cleola Anderiesz, CEO of National Breast Cancer Foundation, Zara Lawless, CEO of Mother’s Day Classic and Robin Penty, at the start line in Melbourne

OCRF CEO Robin Penty, OCA CEO, Assoc. Prof. Anna Boltong and ANZGOG CEO Alison Evans at 2024 Teal Ribbon Parliamentary Breakfast

18

|

Ovarian Cancer Research Foundation

MULTIPLIER EFFECT ‘Partnerships complement our organisational values and purpose and help us to connect with new and existing audiences, contributing enormously to our reach and cut-through.’

Annual report 2023–24

|

19

Major partnerships The power of partnerships Strategic partnerships have always played an enormous role in supporting the OCRF to raise funds and awareness, and 2024 was no exception. These partnerships complement our organisational values and purpose and help us to connect with new and existing audiences, contributing enormously to our reach and cut-through.

Stepping up to the partnership plate this year were many of our long term and highly valued partners, and some exciting new ones, collectively raising $2.14 million for the OCRF. From the glamorous, influencer-led strategy of the iconic Witchery White Shirt campaign now in its 16th year and the beautiful storytelling of the Georg Jensen OCRF pendant campaign, to stalwart supporters such as Simson Cards and great new initiatives with Darrell Lea, Digga Socks, AIA Australia, and of course the ground-breaking partnership with Mother’s Day Classic, each partnership is unique. Every one of them helps tell the story of why ovarian cancer research matters and provides ways for people from all walks of life to get involved.

Eleanor Pendleton, Sara Crampton, Sam Harris, ambassador Georgie Beck in 2023 Georg Jensen campaign

20

|

Ovarian Cancer Research Foundation

Darrell Lea’s chocolate Eggs for Ovaries

Eggs-traordinary Partnership Easter in 2024 became a little bit sweeter with beloved Australian confectionery company, Darrell Lea partnering with the OCRF for the first time, creating a special OCRF Australian-made Milk Chocolate Egg. Sold exclusively in Coles’ supermarkets across the country, the limited-edition eggs donated 20c from each sale to the OCRF. The ‘Eggs for Ovaries’ campaign came to life across our website, email, print, radio, digital display and social channels with the help of OCRF ambassadors Vali Creus, Graham Winbank, Liv Curtis, and Rhiannon Anderson sharing their personal stories.

The inaugural Eggs for Ovaries campaign in partnership with Darrell Lea resulted in a sellthrough of 100,000 eggs and a donation of over $20,000 for the OCRF, marking it as one of the most successful new product launches in Coles in recent years.

Digga’s Ovarian Cancer Socks Major partner Digga Australia developed and sold a limited-edition box set of three specially designed Ovarian Cancer Socks with 100 per cent of net proceeds donated to the OCRF. To mark the launch of annual nation-wide advocacy month, Ovarian Cancer Awareness Month, Digga Australia announced a contribution of more than $22,000 to the OCRF from the sales of these special socks. An exceptional effort.

A new range of sock designs by Digga is set to launch late 2024.

Georg Jensen’s 2023 campaign: It Takes a Village For the ninth consecutive year, the OCRF partnered with Danish luxury brand, Georg Jensen, to bring a special and heartfelt campaign to life in August 2023, raising vital ovarian cancer research awareness and funds through the promotion of a specially designed OCRF pendant.

Grounded by the personal story of ambassador, NSW mother of three, and ovarian cancer patient, Georgie Beck, the 2023 campaign theme was, It Takes A Village. In a deeply moving and striking campaign video and stills captured by Gritty Pretty Productions, Georgie bravely retells her story of diagnosis, treatment and how the loved ones around her continue to be a village of unwavering support.

A conversation starter and powerful symbol of unwavering commitment – the 2023 Georg Jensen OCRF pendant was crafted in both sterling silver and 18 karat yellow gold, Georg Jensen has created a pendant to signify continuous hope, commitment and our collective mission.

As of June 2024, Georg Jensen has contributed more than $500,000 from pendant sales to the OCRF.

Cards that care Our partnership with Simson Cards continued throughout 2024, building on more than a decade of fundraising through the design and sale of two special OCRF-branded card ranges per year – one for Mother’s Day and the other for the Christmas and holiday season. Since 2010, Simson has supported the OCRF with more than half a million dollars in donations from the sale of these cards.

Importantly, the cards also raise crucial awareness of our organisation and this insidious disease, with cards specially marked with the OCRF logo and message reaching people all over Australia.

“My village has given me strength and resilience to live my best life.”

– Georgie Beck, OCRF Ambassador

Annual report 2023–24

|

21

Mother’s Day Classic fuels ovarian cancer research

MDC NEWS

2,430 media mentions

75 events across Australia 85,000 participants

$1.2m raised for ovarian cancer research

213m potential news reach

For 26 years, the Mother’s Day Classic (MDC), has been a cherished national event that unites Australians in a powerful show of support for breast cancer research via the National Breast Cancer Foundation (NBCF). Since its inception in 1998 by Women in Super, the MDC has attracted more than 1.7 million participants nationwide and raised a staggering $47.3 million for cancer research. Thanks to this generosity and community support, the five-year relative survival rate for breast cancer patients has climbed from 84 per cent to 92 per cent – an aspirational and remarkable feat.

A group of teal walkers at 2024 Mother’s Day Classic event

22

|

Ovarian Cancer Research Foundation

So it was with immense excitement that in August 2023, the OCRF announced that for the firsttime in the Mother’s Day Classic history, that the event was extending its impact to ovarian cancer – embracing the OCRF as a second beneficiary alongside the NBCF. This marked the beginning of a powerful union of two communities that are driven to improve outcomes for women – whether they are diagnosed with ovarian or breast cancer.

With ovarian cancer survival rates still languishing below 50 per cent, the hope is that the event will provide a similar boost to that achieved for breast cancer.

On Sunday 12 May, more than 85,000 Australians participated in events across 75 locations nationwide. The atmosphere was electric — amid a sea of breast cancer pink there were sparkles of silver and teal to symbolise ovarian cancer for the first time. The numbers represented a 30 per cent increase in participation on the previous year – a true show of solidarity and the embrace of the ovarian cancer community from the breast cancer community in a warm pink hug.

This was also reflected in the final fundraising tally, too. $3.3 million was raised by the Mother’s Day Classic community, with a staggering $1.2 million generated for ovarian cancer research. A sensational effort that exceeded our expectations.

With an Australia-wide presence, a longstanding legacy, exemplary funding history and multiple physical events in each state, this new partnership with the Mother’s Day Classic will give the OCRF a new national platform.

Honouring the legacy of Helen Powell Walk With Women, the original fundraising walk event for the OCRF was the brainchild of ovarian cancer patient, advocate and ambassador Helen Powell. Helen began the walk in 2016 following her own diagnosis with ovarian cancer. A 30kmlength course along the picturesque Mornington Peninsula, the event grew year on year to over 200 walkers.

Devastatingly, Helen passed away in 2020 from ovarian cancer. Her wish was for the walk to continue and to grow.

Helen’s dream of a national event supporting women’s health, including ovarian cancer, has been realised with Walk With Women now absorbed to enhance the Mother’s Day Classic event. On Sunday 12 May 2024, we joined the MDC and walked in honour of Helen, and the many other women who have faced or are facing ovarian cancer across Australia.

The OCRF looks forward to joining the event again as a beneficiary alongside the NBCF in May 2025.

OCRF ambassador Grace Scoleri (right) and friend celebrate new connections at MDC

OCRF ambassador, the late Helen Powell, founder of Walk With Women

Annual report 2023–24

|

23

Sixteen years of the iconic White Shirt Campaign The annual White Shirt Campaign in partnership with Australian fashion brand Witchery launched in mid-April 2024. Boasting the largest ambassador line-up in the campaign’s history, more than 40 influential women including OCRF funded researcher Professor Stacey Edwards, and ambassadors Grace Scoleri, Emily Jol, and Amelia, Laura and Anabel Flynn, proudly lent their voices to the 2024 campaign. Other new and returning ambassadors included Pip Edwards, Julie Bishop, Dami Im, Emma Watkins, Eleanor Pendleton, Maria Thattil, Jelena Dokic, Melissa Leong and TV Personalities Sarah Abo, Brooke Boney, Sylvia Jeffreys and Allison Langdon.

The official campaign launch took place at the Sydney Opera House, with media, campaign ambassadors, creators, talent and influencers descending on the iconic landmark for the occasion.

Honouring the legacy of Leane Flynn, special printed garment tags acknowledged the OCRF and White Shirt Campaign ambassador’s unparalleled commitment, contribution and dedication to the cause and campaign over the years.

The 2024 collection extended to two new 100 per cent organic cotton white shirt styles, with Witchery donating 100 per cent of gross proceeds from every sale to the OCRF. As of 30 June 2024, sales of this year’s shirts reached over $719k in donations.

Amplified across social media, outdoor advertising, radio, podcasts, print and digital media, the 2024 campaign not only drove sales of Witchery white shirts, but also raised critical awareness and put ovarian cancer in the national spotlight across the nation. This amplification resulted in more than 239 million combined impressions, 152 million PR impressions, 64 PR placements and more than $6.5 million in PR value.

With the 2024 campaign culminating on World Ovarian Cancer Day, 8 May, Witchery held a special head office event at Witchery headquarters.

Featuring a panel discussion with OCRF ambassadors Emily Jol, Grace Scoleri, ovarian cancer researcher Dr Maree Bilandzic and tennis great and author, Jelena Dokic, hosted by media talent Olivia Molly Rogers, the event was a momentous occasion to bring Witchery and OCRF staff together to celebrate their contribution to the campaign and, more broadly, progress in ovarian cancer research.

International acclaim The Witchery and OCRF partnership was recognised in the global stage at the World Ovarian Cancer Coalition Impact Awards as the winner of the ‘Inspiring Collaborations’ category.

A celebration of our longstanding partnership with Witchery, this award recognised how instrumental the White Shirt Campaign has been in ovarian cancer research projects across Australia, raising over $16.7 million in funding - and counting.

More than a fundraising endeavour, this collaboration is a manifestation of a shared belief between charitable organisations and corporate entities, emphasising the critical need for sustained, long-term funding in the realm of medical research.

It’s a testament to the power of collective efforts in driving tangible change and progress.

Left: Melissa Leong in the 2024 Witchery White Shirt Campaign Facing page: Jono, Larsen and Zadie Parker at the 2024 Great Ocean Road Running Festival

24

|

Ovarian Cancer Research Foundation

FUNDRAISING TO FUEL RESEARCH ‘The donor and fundraising community is the beating heart of the OCRF: their stories, experiences, and efforts fuel the OCRF’s investment in research and efforts to improve outcomes for ovarian cancer patients.’

Annual report 2023–24

|

25

Donors, appeals and fundraising The donor and fundraising community is the beating heart of the OCRF: their stories, experiences, and efforts fuel the OCRF’s investment in research and efforts to improve outcomes for ovarian cancer patients. In 2024, these groups stepped up and raised more funds than ever before bringing in $3.6 million in revenue to the OCRF. 2024 was a record year across the board. The OCRF welcomed its first patrons to the new National Research Patrons Program, and continued to receive significant donations from individuals, trusts, foundations and corporate partners alike.

Community fundraising records were broken, with members of our incredible and ever-growing community running, riding, baking, shaving heads, colouring hair, frocking up and more to secure significant funds for ovarian cancer research.

The OCRF is entirely funded by the Australian public through generous donations, community-driven fundraising initiatives, and support for our corporate partnerships. The OCRF is grateful to all our donors and fundraisers for their record-breaking efforts, enabling the OCRF to support vital ovarian cancer research across Australia.

Alisha Henderson hosted a fabulous Bake Off to kick start Frocktober 2023

26

|

Ovarian Cancer Research Foundation

Club 1054 members, TwoScots Recruitment

Frocktober 2023 surpasses the $1 million mark

40-strong team riding 380km in two days for the OCRF, raising over $133,000 and doubling their previous fundraising record of $60,000 set in 2019.

Our Frockers truly stepped up for the 17th annual Frocktober fundraiser. Over 750 participants across Australia frocked up and raised over $1.1 million, the second time this beloved fundraiser has surpassed the $1 million mark. A record 12,500 donors supported our participants (affectionately known as “Frockers”) to reach this significant milestone.

The Strong Legs for Emma team completed a half marathon raising $58,000, in memory of their mum, wife, and friend Emma who sadly passed away from ovarian cancer.

A fabulous bake off hosted by Alisha Henderson kicked off the Frocktober festivities, with entertainer Emma Watkins, media presenter Abbey Gelmi and Masterchef alum Rhiannon Anderson joining forces to share the Frocktober message. 2023 was also the year of the Frocktober event, with frocktail parties, long lunches and community events all around Australia individually raising tens of thousands of dollars, including Rhiannon Anderson’s inaugural Silver Lining Long Lunch, which raised $40,000 for the OCRF.

Special mention to Jonathon Parker, Callum Brooks, Estelle Pham and Steven Mallia, who all raised over $10,000 for the OCRF at their respective multi-charity events.

Cabal Club reaches new heights The OCRF is proud to be the longstanding beneficiary of the Cabal Club Ladies Luncheon, with the event raising close to a quarter of a million dollars for ovarian cancer research over the last 10 years. In 2023, Cabal Club raised over $50,000 for the OCRF through raffle tickets, auction items and ticket sales, marking one of the strongest years yet.

The top fundraiser for the year was Teal 4 Tirion which raised an incredible $212,000 (story below).

Club 1054 and regular giving provides backbone support In September 2023, OCRF launched Club 1054, a business donor network backed by AIA Australia through the AIA Impact Program, as part of their substantial financial and in-kind support of OCRF. Club 1054 aims to recruit 1,054 corporate donors contributing $1,054 annually, generating over $1 million per year for ovarian cancer research.

The name represents the annual ovarian cancer deaths in Australia—a number we aim to reduce.

Through Club 1054 and The Lab monthly giving program, regular donors provided OCRF with over $160,000 in stable support this year. Thank you!

Multi-charity events shine

OCRF donor promise

Multi-charity events continue to provide an uplift in funds, and in 2023-2024 close to 700 members of Team OCRF raised over $120,000 for ovarian cancer research. While the individual reasons for entering these physical challenges may vary, every member joined forces to raise funds for ovarian cancer research. The 2023 Nike Melbourne Marathon Festival also recorded a record result for the OCRF, with over $50,000 raised by 449 participants.

In 2024, the OCRF committed to a new donor promise, setting out our pledge to donors that they can trust us to be fair, honest and open and to treat them with respect and sensitivity. Read the promise on our website.

Community fundraising reaches new heights

Scan the QR code to learn more

Community fundraising continues to be a huge contributor for the OCRF, with fundraisers across Australia raising over $488,000 this year. Notable fundraisers include The King’s Men ride, with the

Annual report 2023–24

|

27

Major donors launch our new OCRF Patrons Program In June, Grace and Charley Scoleri and their family became the inaugural patrons of the new OCRF Patrons Program.

Our community understands the systemic underfunding of ovarian cancer research and this program aims to boost the pool of ongoing, available funds for the OCRF National Research Grants Scheme, enabling more high-quality ovarian cancer research to be supported each year.

Grace is living with ovarian cancer having been diagnosed with stage 3 ovarian cancer in July 2020.

She had extensive treatment and spent three years in remission, however she experienced a recurrence in November 2023, and currently is back in treatment. Although she was aware of ovarian cancer, it wasn’t until she was diagnosed herself that she understood the frustrating lack of progress and research into treatments for the disease.

As a result, the Teal 4 Tirion page raised over $200,000, making it the single largest community fundraising page in OCRF history. This incredible fundraising tally was achieved by the girls’ and their families’ tireless advocacy and generous storytelling, inspiring more than 1,760 people to generously donate to their fundraising page, including some major single donations of more than $15,000.

Thankfully Tirion is now cancer free, and Chloe is looking to continue advocating for women’s health now and into the future.

Most successful end of financial year appeal in OCRF history Our 2024 End of Financial Year Appeal marked an incredible end to the year, raising over $700,000 for the OCRF – doubling last year’s result.

It was Grace’s determination to help and create a lasting impact for future generations that led her to the OCRF. Now as a patron, Grace will continue her support of critical ovarian cancer research and raise awareness of the disease.

OCRF ambassador Liv Curtis, courageously shared her ovarian cancer story providing a highly personal lens and insight into the impact of the disease, which was a key driver for the appeal. Liv was diagnosed at just 35 years old. In her initial surgery five consultants from different specialties spent nine hours removing the three kilogram tumour. More surgeries and treatment ensued, and she is currently on a clinical trial that is limiting the disease progression.

“I made it my mission to be heavily involved and focus on the research side to aid women in the generations to come. The more money we invest in research, the brighter their future will be,” she said.

Liv’s story also garnered media attention, with 9Honey and Mamamia both interviewing Liv and sharing her story with their readers to support the EOFY appeal.

Teal 4 Tirion breaks OCRF fundraising records

The EOFY appeal also featured 2024 National Research Grants Scheme recipient Professor Kristen Radford to highlight the potential for innovative treatments. Her story outlined her work in immunotherapy, explaining how her research is investigating a personalised vaccine that could train the immune system to recognise ovarian cancer cells and mount a response.

On World Ovarian Cancer Day 11year-old Chloe shaved her long locks off on in support of her best friend, Tirion, who had been diagnosed with stage four of a rare ovarian cancer in December 2023.

The fundraiser was initially planned for the Student Representative Council at their New South Wales school, with a modest goal of $2,000 for Chloe to shave her hair. However, thanks to media support led by Ben Fordham at 2GB Radio Sydney, and a groundswell of community concern and interest, the momentum grew and grew.

The success of the 2024 EOFY Appeal is also due to the incredible matching donors of the Quinn Femelle Foundation and Mr Hamid Daghighi, who through donations of $50,000 and $100,000 respectively, matched donations up to $150,000.

Facing page: Ambassadors Kristen Watson and Diana Unkovich

28

|

Ovarian Cancer Research Foundation

STRENGTH IN COMMUNITY ‘OCRF is driven by its community of supporters who contribute in myriad ways. There is an enormous sense of connection and shared commitment, and a feeling of belonging that makes this organisation particularly special.’

Annual report 2023–24

|

29

OCRF community A community stepping up OCRF is fuelled by its community of supporters who contribute in myriad ways. There is an enormous sense of connection and shared commitment, and a feeling of belonging that makes this organisation particularly special.

Sharing and amplifying the personal stories of the ovarian cancer community has been instrumental in the OCRF’s advocacy work to drive deeper understanding of the disease, more awareness and generating funding for medical research. During the year, OCRF ambassadors across Australia spoke at local fundraising events, interviewed with media for key announcements, and featured in nation-wide campaigns, such as the White Shirt Campaign and Mother’s Day Classic.

This community extends to a long list of in-kind supporters across business, the media and the health sector, who help amplify our messages and enable the OCRF to make an impact that belies its size.

Ambassadors Alana Chantry, Georgie Beck and Kylie Murphy from Little Party Dress at 2024 Silver Style Event

30

|

Ovarian Cancer Research Foundation

Ambassador Jordan Turner (right) with Sheridan Webb at fundraiser in Barwon Heads

Celebrating Silver Style The annual Silver Style event is an opportunity for the OCRF to say a special thank you to key supporters, and a moment to gather in person and celebrate achievements from the past year.

This year we hosted the Silver Style event in the Isabella Fraser Room of the Melbourne State Library in March surrounded by our close community of fundraisers, donors, researchers, institutes, major partners, ambassadors, Board members, committees and others.

This event also provided the perfect occasion to announce the 2024 National Research Grants Scheme’s three major grant recipients – Dr Dane Cheasley, Professor Kristen Radford and Professor Carlos Salomon Gallo. It was also an opportunity to reflect on the key milestones and recent announcements, and a look forward to what’s on the horizon for our small but mighty organisation.

Hear their voice With more than 85 active members nationwide, OCRF community ambassadors play a key role in giving voice to ovarian cancer, helping to prompt national conversation and raise awareness.

As our group of Community Ambassadors continues to expand and develop, the OCRF hosts regular training sessions to ensure ambassadors are armed with all the necessary information, skills and tools to support their advocacy. In March, the OCRF held an ambassador training day at AIA Vitality head offices in Melbourne with more than 20 ambassadors in attendance.

The day included OCRF staff introductions, a breakdown and deeper dive into the current OCRF funded research, ways of working and expectations, storytelling and media training by PR Agency AMPR, and a public speaking session.

During the year, ambassadors represented the OCRF across key national campaigns, announcements, appeals, media interviews and events.

We acknowledge and sincerely thank each and every ambassador for their efforts. Special mention to those who went above and beyond, volunteering their time to share their personal stories, to galvanise their networks and wider community to raise awareness and research funding in 2023-24: Georgie Beck, Amelia Higgs, Tora Murphy, Liv Curtis, Rhiannon Anderson, Shabnam Gujadhur, Rhiannon Anderson, Graham Winbank, Emily Jol, Grace Scoleri, Amelia, Laura and Anabel Flynn, Tarni Tsimeras, Sarah Hayward, Marie-Claire Grady, Vali Creus.

Vale We extend our heartfelt condolences to the families and friends of Annabel Dance and Jordana (Jordy) Thompson who sadly passed away in the past year. Both served as ambassadors for the OCRF. Annabel and Jordy were committed to seeing better outcomes for ovarian cancer in the future, despite the disease cutting their own lives short.

We are deeply grateful to these selfless and courageous women for their profound impact, sharing their personal stories of ovarian cancer for the good of others.

Vale, Jordy and Annabel.

The 2024 OCRF Silver Style event at the Victorian State Library

Annual report 2023–24

|

31

OCRF in the news Raising awareness and drawing attention to ovarian cancer and the urgent need for more research is mission critical for the OCRF. Marketing, social media, PR and publicity activations are essential to the success of our campaigns, partnerships and fundraising.

Editorial PR and organic social media play an increasingly important role in raising awareness of OCRF’s role, and to provide a platform for our ambassadors’ stories.

2024 was a big year for the OCRF on the media front with coverage across print, digital, radio and television, ranging from grants announcements making national news, fundraisers on the radio waves, ambassador interviews in national press and campaigns reaching millions on social media.

NEWS

1.4b reach 1,930 media mentions

Over 37,500 social media followers

Our marketing initiatives are amplified across a range of advertising and promotional channels, receiving generous in-kind support from fantastic long-term supporters including Nova Entertainment, oOh! Media and Frankie magazine, which multiplies the value of our investment many times over.

Facing page: Donor and Partnerships Director, Georgie Herbert, CEO Robin Penty, Deputy Chairperson Anne-Marie O’Loghlin holding the 2024 Mother’s Day Classic cheque

Good friends Chloe and Tirion raised over $200k and attracted national media coverage for the Teal 4 Tirion fundraiser

32

|

Ovarian Cancer Research Foundation

Tennis legend and author Jelena Dokic was one of 45 Witchery White Shirt campaign ambassadors who helped to attract PR value of $6.5 million for the 2024 campaign

FINANCIAL STATEMENTS ACKNOWLEDGEMENTS GOVERNANCE Annual report 2023–24

|

33

Financial statements: overview General information OCRF is a not-for-profit entity for the purpose of preparing the financial statements.

The Ovarian Cancer Research Foundation Limited (‘Ovarian Cancer Research Foundation’, ‘OCRF’) is a company limited by guarantee and incorporated under the Corporations Act. The company is domiciled in Australia and the address of its registered office is U2 - 59 Keele St Collingwood Victoria 3066.

These financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards – Simplified Disclosures made by the Australian Accounting Standards Board (AASB) and the Australian Charities and Not-for-Profits Commission Act 2012.

Explanatory notes

Significant changes in state of affairs No significant change in the state of affairs of the OCRF occurred during the financial year.

• Australian Cancer Research Foundation • Cancer Australia As per the OCRF Investment Policy 2022, forward research grant commitments are set aside for the duration of the research project. However, all grants are subject to annual review and reporting requirements, therefore do not represent Liabilities of the OCRF at 30 June 2024. Instead, these are included as Assets on the Statement of Financial Position (refer pg 35).

Operating result Total revenue for the OCRF for the year ended 30 June 2024 is $7,685,731, comprised of $5,996, 753 in revenue raised and pro-bono (in-kind) support of $1,688,978 (2023 total: $8,409,474). The operating surplus for the year ended 30 June 2024 is $860,428 (2023 was an operating surplus of $1,168,175.

Board of Directors’ Declaration Ovarian Cancer Research Foundation for the year ended 30 June 2024

Events subsequent to reporting date

The Directors of Ovarian Cancer Research Foundation (OCRF) declare that in their opinion:

In August 2024, The Mother’s Day Classic Foundation (MDCF) announced the outcome of the May 2024 Mother’s Day Classic event, with the OCRF as recipient of a $1.2m donation from the Mother’s Day Classic Foundation.

(a) the attached financial statements and notes, comply with the Corporations Act 2001, the Australian Accounting Standards - Simplified Disclosures, the Australian Charities and Not-for-profits Commission Act 2012, the Corporations Regulations 2001 and other mandatory professional reporting requirements.

Management deemed the announcement as an adjusting subsequent event in response to conditions that existed prior to year-end, noting an August 2023 agreement in place with the MDCF and many publicised fundraising events that took place across Australia in May 2024.

Notes regarding forward research grant commitments As part of the ongoing research grants program, as at balance date, the OCRF has forward commitments of $4.169 million across multi-years to the following research institutions, either in direct grants or collaborative funding with sector peers: • University of Queensland (QLD) • University of Adelaide (SA) • University of Griffith (QLD) • University of Melbourne (VIC) • Hudson Institute of Medical Research (VIC)

34

|

Ovarian Cancer Research Foundation

(b) the attached financial statements and notes gives a true and fair view of the OCRF financial position as at 30 June 2024 and of its performance for the financial year ended on that date; and (c) there are reasonable grounds to believe that the OCRF will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the Directors made pursuant with subsection 60.15 (2) of the Australian Charities and Not-for-profits Commission Regulations 2013.

Julie Toop (Director) Philip Herbert (Director) 14 October 2024 14 October 2024

Statement of Financial Position Ovarian Cancer Research Foundation Limited As at 30 June 2024

Account

2024 ($)

2023 ($)

Cash and Cash Equivalents

1,993,718

818,876

Trade and Other Receivables

2,117,402

1,356,488

Financial Assets

3,839,048

4,454,225

Assets Current Assets

Other Current Assets

262,315

269,696

Total Current Assets

8,212,484

6,899,285

3,895

4,229

Right of Use Asset

218,451

299,849

Total Non-Current Assets

222,345

304,078

8,434,829

7,203,363

Lease Liability (CL)

53,942

58,290

Trade and Other Payables

514,136

71,677

Provisions

43,500

40,297

Total Current Liabilities

611,578

170,264

172,190

241,559

Non-Current Assets Plant and Equipment

Total Assets

Liabilities Current Liabilities

Non-Current Liabilities Lease Liability (NCL) Provisions

33,858

33,497

Total Non-Current Liabilities

206,048

275,056

Total Liabilities

817,626

445,320

7,617,203

6,758,043

Accumulated Funds

4,617,203

3,758,043

Reserves

3,000,000

3,000,000

Total Equity

7,617,203

6,758,043

Net Assets

Equity

The accompanying notes on page 34 form part of these financial statements.

Annual report 2023–24

|

35

Statement of Profit or Loss and Retained Earnings Ovarian Cancer Research Foundation Limited For the year ended 30 June 2024

Account

2024 ($)

2023 ($)

Revenue

5,751,889

4,962,979

Pro-Bono Income

1,688,978

3,274,444

Total Income

7,440,867

8,237,422

Finance Income

244,864

172,052

Total Other Income

244,864

172,052

7,685,731

8,409,474

Income

Other Income

Total Income for the year

Expenditure Finance Costs

11,351

3,542

Depreciation and Amortisation

86,164

16,894

Digital Systems

78,424

175,936

Employee Costs

1,648,663

1,067,817

Marketing Expenses

1,033,300

1,164,861

Operating Expenses

277,896

208,964

Pro-Bono Expenses

1,688,978

3,274,444

Auditors’ Remuneration

5,000

3,000

Total Expenditure

4,829,775

5,915,457

Profit before grant payments

2,855,956

2,494,017

Grants paid during the year

1,995,528

1,325,042

Total Grant Payments

1,995,528

1,325,042

Total comprehensive profit/(loss) for the year

860,428

1,168,975

Account

2024 ($)

2023 ($)

Retained Earnings at the beginning of the reporting period

3,758,043

2,589,068

Reserves

3,000,000

3,000,000

860,428

1,168,975

(1,268)

0

7,617,203

6,758,043

Grant Payments

Retained Earnings

Current year Earnings Retained Earnings adjustment line Retained Earnings at the end of the reporting period The accompanying notes on page 34 form part of these financial statements.

36

|

Ovarian Cancer Research Foundation

Corporate Partners and Supporters The OCRF gratefully acknowledges the paid and in-kind donations of the OCRF’s corporate partners, supporters and sponsors. Corporate support is vital to ensuring the OCRF can maximise our research investment and maintain a sustainable and effective organisation.

Principal partners: $100k+

Mother’s Day Classic Foundation Witchery

Major partners: $50-$99k

AIA Insurance

Darrell Lea

Georg Jensen

Digga

Simson Cards

Corporate donors: $25-$49k

Corporate donors: $12-$25k

Two Scots Recruitment

Media partners (in kind value $50k+)

oOh! Media

Nova Entertainment

Media supporters (in kind value $10k-$50k) AMPR Frankie

Annual report 2023–24

|

37

Thank you The OCRF acknowledges and thanks everyone who has supported and contributed so generously to fund our work to overcome ovarian cancer.

June Hunter

We would like to particularly recognise these major donors, fundraisers and those who have gone the extra mile in the name of ovarian cancer research.

Maureen Stevenson

Principal Patron ($100k +)

Michael Phillips

Leonie Nossbaum Louise Parsons Melbourne Football Club Coterie Michael Bainbridge

Hamid Daghighi

Pangortynian Association

OCRF Patrons ($50k - $99,999)

Samantha Butt

River Birch Foundation

Grace and Charley Scoleri and family

Spinifex Trust

Peter South

Stephen Cuthbert

CJQ Private

Tanya Mendel

Individual and institutional donors $5k - $20k

The GP Harris Foundation

Anne O’Neil Anne-Marie O’Loghlin

Therese Mason Todd Brownlow

Ann-Maree & Rodney Wubben

Bequests

Anthony Smith

Estate of the late Joan Ann Gracie

Arthur Laundy (individual donation)

Estate of the late Paula Winchester

Barry Thatcher

High achieving fundraisers $10k +

Carretta Mason Foundation Cindy and Terry Lissiman Curanda Angels Foundation Daniel Shanahan David McManus Em Campbell-Pretty Emily Montgomery Gail Macklin Harry Cohney Charitable Foundation Hupert Family Foundation Ian Wanless Jane Rich John Cook John Durlacher John Holding Johnstone Family Foundation Josh Slattery

38

|

Ovarian Cancer Research Foundation

Alex Solterbeck Amelia Higgs Anna Kelly Ashlee Griffiths Cabal Club Cal Brooks Frock You Cancer, Freo Tammy Style Georgie Beck GHD South Queensland Helen’s Hope Afternoon Tea 2023 In memory of Jen Lobo Jemima Leydon Jono Parker Karis Luckhurst Leigh Cardinal Linda’s Angels

Lindy’s White Shirt Morning Tea Live and Let’s Live – Niki Peinke LoveYourOvaries Marie-Claire Grady O-Vary Long Walk for Tora Remy Samin Sam Pidgeon Silver Lining Long Lunch Strong Legs for Emma Teal 4 Tirion The Kings Men Ride Different Trek for Yvette Wagga Ovarian Cancer Awareness Group

Corporate supporters $1k-10k Accent Group – Stamp Your Feet Foundation Acoustic Logic Charles Parsons & Co Pty Ltd Camera Warehouse Macquarie Bank Monday Swimwear SA Power Networks Employee Foundation The Big Hug Box Unique Luxury Car Hire Vantage Property Wilson Asset Management

Women in Finance Frocktober event

Club 1054 Founding members

Women’s Association Annual Lunch fundraising

Acorn Psychology

Volunteers

AIA Financial Wellbeing

Chloe Spitalnic Grace Scoleri Jemma Spicer Lauren Brooker Lily Boston Lindy Spicer Lori Phillips Lyn Johnson Simon Higham Simone Gianarelli

Bastion Agency Blissed Out Movement Pty Ltd BW Thompson Electrical Pty Ltd Dr Sheryl Wagstaff Charlie Holiday Lowe Financial Group Maju Advisory Pty Ltd MBS Insurance PIXO The Growth Project

Tim Prudden Trisha Crichton

Frocktober Hall of Fame 10 years plus Amy Brown Eilis Hughes Jen Sheridan Jill Berry Krisiti Day Louisa Robertson Sam Pidgeon Tegan Johnson

Corporate donors $10k and above Avionics Pty Ltd Manildra Mills Flour Pty Ltd Fashion parade at the 2023 Love Your Ovaries Frocktober fundraising event

Annual report 2023–24

|

39

Governance Our Governance – OCRF Board The OCRF is governed by a Board supported by four expert subcommittees. We are grateful to all our contributing members, who give their time freely and passionately to guide the OCRF.

Board Directors All reappointed at June 2024.

Ms Julie Toop, Chairperson – Appointed 2006

Ms Robin Penty became Secretary of the Ovarian Cancer Research Foundation in June 2023.

Board Observer Melanie Hayden – Appointed 17/6/24

Outgoing Board Members The OCRF would like to recognise and thank both Ms Sarah Saunders and The Honourable Lisa Neville for their contributions to the OCRF board.

Ms Anne-Marie O’Loghlin, Deputy Chairperson – Appointed 2019 Dr Geraldine Goss – Appointed 2007 Ms Sharon McCrohan – Appointed 2017 Mr Philip Herbert Treasurer – Appointed 2021 Ms Colleen Maguire – Appointed 2021 Dr Nicole Krzys – Appointed 2022 Dr Paul Kenny – Appointed 2022 Ms Karleen Radford – Appointed 2024

OCRF staff members at the 2024 Mother’s Day Classic

40

|

Ovarian Cancer Research Foundation

Scan the QR code to learn more

The OCRF acknowledges and thanks all external members of our four advisory committees for their strategic and technical guidance throughout the year. The Marketing and Fundraising Committee was retired this year, with those activities being undertaken by a larger internal team and the Board, so we offer particular thanks to those long-serving members for their time and input to OCRF’s success.

Outgoing ISAC Members

Finance, Risk and Audit Committee

Dr Francine Marques

Mr Phillip Herbert – Chairperson

Jordan Turner

Ms Julie Toop

Vali Creus

Mr Menchi Schneier

Jemima Leydon

Mr Justin Flynn

Sirin Steele

Ms Ren Barlow

The OCRF would like to recognise and thank Associate Professor Daniela Dinulescu for her contributions to the ISAC.

Consumer Representative Panel Ms Anne-Marie O’Loghlin – Chairperson Daniella Brasacchio

Ms Lynda Rogers

The OCRF team

Mr Maurice Spicer

Robin Penty, CEO

Mr Michael Elsworth

Marketing and Fundraising Committee Ms Sharon McCrohan – Chairperson Ms Anne-Marie O’Loghlin

Finance and Governance Lisa Panetta, Finance and Governance Manager Liam O’Launaigh, Foundation Coordinator

Ms Jennifer Petropoulos

Research

Mr Justin Smith

David Hunt, Research Director

Ms Rosalind Willett

Dr Amy Wilson, Research Advisor

Ms Ren Barlow

Caitlin Leishman, Knowledge Translation Lead

Ms Julie Toop

Donor and Partnerships

Ms Colleen Maguire

International Scientific Advisory Committee Dr Paul Kenny – Chairperson Dr Geraldine Goss Dr Nicole Krzys Professor Iain McNeish

Georgie Herbert, Donor and Partnerships Director Aimee Kendall, Business Development and Partnerships Lead Adel Botfield, Events and Donor Coordinator Abigail Russell, Fundraising, Marketing and Engagement Coordinator

Professor Matthias Ernst

Communications

Professor Kenneth P. Nephew

Avalee Weir, Senior Communications Director

Professor Sandra Orsulic Professor Magdalena Plebanski

Jemma Gomularz, Communications and Engagement Lead

Associate Professor Anirban Mitra

Bernaba Balili, Digital Marketing Lead

Associate Professor Honami Naora

Kate Grant, Communications Coordinator

Associate Professor John Liao Professor Samual Mok

Annual report 2023–24

|

41

The challenge we face Ovarian cancer makes up a

quarter

of gynaecological cancer

diagnoses, but accounts for

almost half

of deaths

40%

of ovarian cancer cases are in women under 60 years old

49%

five-year survival rate for ovarian cancer

Ovarian cancer is the only cancer in the

top 10 conditions

that could close the women’s health gap globally (GDP)1

Ovarian cancer is the

5th most lethal (survivability), but

12th in terms of the funding

Ovarian cancer incidence is set to rise by

66%

in our region over the next

25 years

to-lethality ratio in Australia

1. McKinsey Report 2024, Closing the women’s health gap: A $1 trillion opportunity to improve lives and economies

Facing page: Ambassador Georgie Beck (right) with friend Sue in the 2023 Georg Jensen campaign

42

|

Ovarian Cancer Research Foundation

Annual report 2023–24

|

43

2/59 Keele Street Collingwood VIC 3066 Australia ACN 130 949 834 ABN 37 130 949 834

www.ocrf.com.au